Stocks · News reference
Kestra Medical Techs (NASDAQ:KMTS) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.62) by 20.97 percent. This is a 50 percent decrease over losses of $(0.50) per share
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Traci S. Umberger, Director, General Counsel and Chief Administrative Officer of Kestra Medical Technologies, sold 100,000 shares of company stock on October 21, 2026.
Brian Daniel Webster, President and CEO of Kestra Medical Technologies, sold 15,000 shares of the company's stock on October 20, 2026.
Evercore ISI Group analyst Vijay Kumar initiates coverage on Kestra Medical Techs (NASDAQ:KMTS) with a Outperform rating and announces Price Target of $34.
Kestra Medical fell 8.6% after missing earnings estimates despite beating sales forecasts; several other stocks also declined premarket.